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Abstract
Background: Continuous hemodiafiltration (CHDF) is used as renal replacement therapy for critically ill patients
with renal failure, and to treat hypercytokinemia. Since CHDF also clears therapeutic agents, drug pharmacokinetics
(PK) should be dependent upon CHDF conditions. Although the antibiotic biapenem (BIPM) is used in patients
undergoing CHDF, the optimal therapeutic regimen in such patients has not been fully clarified. In this study,
we investigated the PK of BIPM in patients with various levels of renal function undergoing CHDF with polysulfone
(PS) membrane, and used PK models to identify the optimal administration regimen.
Methods: BIPM (300 mg) was administered by infusion in patients undergoing CHDF (n = 7). Blood and
filtrate-dialysate were collected for compartment and non-compartment analysis.
Results: The sieving coefficient of PS membrane was 1.00 ± 0.06 (mean ± S.D., n = 7), and CHDF clearance of BIPM
was found to be the sum of the dialysate flow rate (QD) and filtrate flow rate (QF). Non-CHDF clearance showed
inter-individual variability (4.82 ± 2.48 L/h), depending on residual renal function and non-renal clearance. Based on
the average PK parameters obtained with a compartmental model, maximal kill end point (over 40 % T >MIC4 μg/mL)
was achieved with regimens of 300 mg every 6 h, 300 mg every 8 h, and 600 mg every 12 h. Monte Carlo simulation
indicated that 300 mg infusion for 1 h every 6 h was optimal, and the probability of target attainment at MIC2 μg/mL
was 90.2 %.
Conclusions: Our results establish the optimal regimen of BIPM in patients with various levels of renal function
undergoing CHDF with a PS membrane.
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Background
Continuous hemodiafiltration (CHDF) is a blood purifi-
cation method that provides alternative functionality for
patients with kidney failure. It removes a wide range of
compounds, ranging from low-molecular-weight prod-
ucts such as urea nitrogen and creatinine to medium-
molecular-weight compounds such as β-2 microglobulin
and cytokines [1, 2]. Therefore, CHDF is widely used in
intensive care units to treat patients with unstable
hemodynamic pathologies, including acute pancreatitis,
fulminant hepatitis, and acute renal failure, as well as to
remove cytokines in sepsis patients, even if they have
normal renal function [3–6]. Since the pharmacokinetics
(PK) of medications may be affected by elimination
through dialysis and filtration during CHDF therapy,
it is necessary to select an appropriate administration
regimen (timing, dose amount, and dose rate) de-
pending upon the conditions of CHDF [7, 8]. It has also
been reported that drug clearance varies depending on
the material of the dialysis membrane [9], and cytokine
clearance is also dependent on the dialysis membrane
material [2].
Biapenem (BIPM) is a carbapenem antibacterial agent
with broad-spectrum, potent activity against Gram-
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positive, Gram-negative, and anaerobic bacteria [10]. It is
not cleaved by dehydropeptidase-1 (DHP-1), unlike other
penem antibiotics such as panipenem and imipenem, and
can be used as a single agent without the need for formu-
lation of a nephrotoxicity-reducing agent or DHP-1 in-
hibitor [11–13]. Carbapenems are classified as time-
dependent antibiotics, and the clinical outcome is closely
correlated with the duration for which the drug concen-
tration remains at or above the minimum inhibitory con-
centration (MIC); the time above the MIC (T >MIC)
needs to be over 20 and 40 % of the dosing interval to
achieve stasis and maximal kill as end points, respectively
[14, 15]. For carbapenem antibiotics, sensitive MIC and
intermediate MIC are defined as ≥ 4 μg/mL and ≥ 8 μg/mL,
respectively [16]. To obtain optimum effects of BIPM, we
need to predict T >MIC from the PK parameters of BIPM.
BIPM is mainly excreted from the kidneys, and clearance of
BIPM in patients with renal failure is decreased to 2.62 L/h,
i.e., approximately 20 % of that of healthy adults [17].
CHDF also alters the clearance of BIPM, and Ikawa et al.
have reported on PK modeling and dosage adaptation of
BIPM during CHDF with a polymethyl methacrylate
(PMMA) membrane in patients with renal failure
[18]. The PK of single BIPM administration was cal-
culated using multi-compartment models, and it was
found that the dose amount and dosing interval were
important factors determining the value of % of T >
MIC. However, their models were applicable only to pa-
tients with renal failure. Since CHDF is also used for pa-
tients with various levels of renal function, models that
take account of this are required. Furthermore, the effects
of other types of filter membrane in CHDF should also be
considered.
In the present study, we developed non-compartmental
and compartmental models for repeated BIPM treatment
in patients with various levels of renal function undergo-
ing CHDF with a polysulfone (PS) membrane, and exam-




This study was approved by the Clinical Research Ethics
Committee of Kanazawa University Hospital (2011–052).
Adult patients older than 20 years who were receiving
CHDF for acute renal failure or removal of cytokines, and
who were prescribed BIPM to treat infection were eligible.
Prior to the start of the investigation, informed consent
was obtained in writing from each participant or his/her
relatives. We excluded patients taking sodium valproate,
or with a history of hypersensitivity to carbapenems or
fourth-generation cephems, or with contraindications for
carbapenems or fourth-generation cephems, or with a his-
tory of epilepsy or central nervous system damage. Seven
patients (5 males, 2 females) were enrolled. Demographic
and medical characteristics of each patient are summa-
rized in Table 1. The glomerular filtration rate (GFR) of
each patient was evaluated before CHDF application.
CHDF
In the present study, a PS hemofilter with a membrane
surface area of 1.3 m2 (EXCELFLO® AEF-13, Asahi Kasei
Medical Co., Japan) was used for hemopurification.
CHDF was performed basically with a blood flow rate
(QB) of 80 mL/min, dialysate flow rate (QD) of 500 mL/h,
substitution flow rate (QS) of 500 mL/h, and filtration flow
rate (QF) of 1000 mL/h, and was regulated appropriately
based on each patient’s status. Sublood-BS® (Fuso Phar-
macy, Inc., Japan) was used as a dialysate and also served
as a substitution fluid for post-dilutional infusion. During
CHDF, nafamostat mesylate was serially administered at a
rate of approximately 20 mg/h to avoid coagulation within
the circuit.
BIPM administration and collection of blood and
filtrate-dialysate samples
Three hundred milligrams of BIPM (Omegacin® 0.3 g,
Meiji Seika Pharma Co., Japan) was administered by intra-
venous drip infusion for 0.5 or 1 h at 6, 8, or 12 h intervals
Table 1 Patient characteristics
Patient Sex Age (years) Ht (cm) BW (kg) BSA (m2) Infusion Interval (hr) Dose (mg) Infusion time (hr) GFR (mL/min/body)
A M 64 167 95.1 2.03 12 300 1 20.4
B M 70 157 53.1 1.50 8 300 1 17.0
C F 33 160 57.5 1.61 12 300 1 15.8
D M 65 166 65.0 1.70 6 300 1 58.8
E M 75 162 47.8 1.45 8 300 1 31.0
F M 55 164 64.8 1.69 6 300 0.5 63.3
G F 80 145 66.7 1.60 8 300 0.5 8.4
Mean 63.1 160.1 64.3 1.65 30.7
SD 15.6 7.5 15.3 0.19 21.9
Ht height; BW body weight; BSA body surface area; GFR glomerular filtration rate (value before CHDF); SD standard deviation
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(Table 1). Blood samples were taken from the blood access
port in the extracorporeal circuit proximal to the filter be-
fore dosing, at 0, 0.5, 1, 2, and 4 h after infusion, and just
before the next infusion. Filtrate-dialysate (FD) samples
were simultaneously collected from the filtrate tube to de-
termine the sieving coefficient (SC) and CHDF clearance.
After collection, each blood sample was centrifuged im-
mediately. The plasma and supernatants of FD samples
were immediately frozen at −80 °C and stored until assay.
Method of quantitative analysis of BIPM
Quantitative analysis of BIPM in plasma and FD was per-
formed using high-performance liquid chromatography
(HPLC) [18]. Briefly, plasma or FD sample (200 μL) was
mixed with 200 μL of 1 M 3-morpholinopropane-1-sul-
fonic acid buffer. An aliquot (300 μL) was transferred to
an ultrafiltration device (Nanosep® Centrifugal Devices
10 K, Pall Life Sciences, USA), and centrifuged at 15,000 g
for 15 min at 15 °C. An aliquot of the ultrafiltered solution
(20 μL) was injected into an HPLC system (Prominence,
Shimadzu Co., Japan) equipped with an Octadecyl silica
column (Shim-pack CLC-ODS 5 μm (150 x 6 i.d.),
Shimadzu Co., Japan) and a UV detector (232 nm). The
mobile phase of 1.5 % acetonitrile and 98.5 % 0.1 M so-
dium acetate buffer (pH 4.6) was delivered isocratically at
a flow rate of 1.0 mL/min. The auto-sampler temperature
was set at 4 °C, and the column temperature at 40 °C. The
calibration curve was linear from 0.1 to 50 μg/mL, and the
lower limit of detection was 0.1 μg/mL.
Calculation of PK parameters of BIPM
Non-compartmental and compartmental analyses were
performed using PK analysis software: Numeric Analysis
Program for Pharmacokinetics (Napp) ver. 2.31 (Depart-
ment of Pharmacy, the University of Tokyo Hospital). The
area under the BIPM concentration-time curve (AUC)
was calculated based on the logarithmic trapezoidal rule.
The SC was determined as AUCFD/AUCplasma. The AUC
after first administration was calculated from 0 h to
infinity, and subsequent AUCs were estimated from
0 h to the start of the next infusion interval, since
the half-life of BIPM in healthy persons is 1 h [19].











where X1, X2 and X3 are the amounts of drug (mg) in
the central, peripheral and hemofilter compartment,
respectively; Rinf is the drug infusion rate (mg/hr); k10
and k30 are the elimination rate constant (hr
−1) from the
central compartment and the hemofilter compartment,
respectively; k12 and k21 are the intercompartmental
transfer rate constants (hr−1); k13 is transfer rate con-
stant (hr−1) from the central compartment to the hemo-
filter compartment.
These equations were used to obtain the following for-
mulas for the drug concentrations (μg/mL) in the central
compartment (C1) and FD (C3) at time t (hr) during and
after administration in the steady state:
(i) 0 ≦ t≦ Tinf
Fig. 1 Multicompartment model for BIPM during CHDF. X1, X2 and
X3 are the amounts of drug in the central, peripheral and hemofilter
compartments, respectively; V1, V2 and V3 are the volumes of the
central compartment, peripheral compartment and hemofilter
cartridge, respectively; Rinf, drug infusion rate; k10, 30, elimination rate
constants; k12, 13, 21, rate constants connecting the compartments
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Where Tinf is the drug infusion time (hr); τ is the
inter-dose interval (hr); V1 is the volume of distribution
of the central compartment; V3 is the blood volume of
the hemofilter cartridge; and α and β are macro rate
constants (hr−1) expressed as α + β = k12 + k21 + k10 + k13,
αβ = k21 · k10 + k21 · k13.
The rate constants k13 and k30 can be expressed as:
k13 ¼ QF þ QDð Þ % SCV 1
k30 ¼ QF þ QDð ÞV 3
Where QF is the filtrate flow rate (L/hr); QD is the di-
alysate flow rate (L/hr).
The clearance in CHDF (CLCHDF) was calculated as
(QF + QD) · SC and the clearance by non-CHDF routes
(CLnon-CHDF) was estimated as k10 · V1.
We modified the formula of Ikawa et al. [18] to in-
clude data obtained not only after the first administra-
tion of BIPM, but also those obtained during repeated
administration of BIPM. The concentration-time data of
BIPM in plasma and FD were concurrently fitted to the
multi-compartment model described above.












Where eGFR is estimated glomerular filtration rate
(mL/min/1.73 m2); BSA is body surface area (m2) [20]; Scr
is serum creatinine concentration (mg/dL); Age is given in
years; Ht is height (cm); BW is body weight (kg). eGFR
was determined just before CHDF application.
Calculation of the PK/PD breakpoint by Monte Carlo
simulation
Monte Carlo simulation was performed with the normal
random number generation function of Microsoft® Excel®
2007 (Microsoft, USA). We generated a population par-
ameter set of 10,000 cases using a mean and variance of
k21, V1, α and β obtained by the standard two-stage
method (compartmental analysis), thereby generating
the BIPM plasma concentration transition of 10,000
cases. After setting the dosing interval and administra-
tion time of BIPM in the above formula (C1), the expos-
ure time for which the BIPM plasma concentration
remained at the MIC was finally calculated as the cumu-
lative percentage over a 24 h period in the BIPM plasma
concentration transition of the 10,000 cases [21–23].
Then, we calculated the number of cases that showed
T >MIC of 40 % or more at each PK/PD target value in
each regimen. Maximum MIC of more than 80 % was
set as the PK/PD breakpoint probability of target attain-
ment (PTA) in each regimen.
Results
In the present study, no adverse events or laboratory ab-
normalities were noted that were definitely attributable
to BIPM.
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SC of the PS membrane was calculated to be 1.00 ±
0.06 by non-compartmental analysis (Table 2). The PK
parameters estimated by compartmental analysis were as
follows: V1, 13.46 ± 5.29 L; k12, 0.75 ± 0.71 h
−1; k21, 0.95 ±
0.27 h−1; k10, 0.39 ± 0.22 h
−1; and k13, 0.13 ± 0.04 h
−1
(Table 3). Figure 2 shows typical fittings between the
plasma and FD concentration time curves obtained by
compartmental analysis and the real values in Pt. A and
Pt. B. Time courses of BIPM concentration in plasma and
FD obtained by compartmental analysis in other pa-
tients also closely fitted the observed values. CLCHDF
and CLnon-CHDF were estimated to be 1.53 ± 0.10 L/h
and 4.86 ± 2.50 L/h, respectively. The inter-individual
variation in CLnon-CHDF was large. The sum of CLCDHFand
CLnon-CHDF, calculated as (QF +QD) · SC and as k10 ·V1, re-
spectively [x], and CLtot obtained by non-compartmental
analysis of the plasma BIPM concentration [y] showed a
good correlation (y = 1.01 x − 0.02, r2 = 1.00), supporting
the validity of the model. As shown in Fig. 3, the correlation
between GFR obtained just before CHDF and CLnon-CHDF
was also high (r2 = 0.97), and the slope and y-intercept were
1.86 and 1.02, respectively. In this study, the number of pa-
tients who showed T >MIC4 μg/mL values of 40 % or more
was 6, and one was in the range of 20 to 40 %. Moreover,
the number of patients with T >MIC8 μg/mL values of more
than 40 % was one, and 6 were in the range of 20 to 40 %.
Figure 4 shows % of T >MIC values in plasma of
patients undergoing CHDF based on the average param-
eters of the multi-compartment models on various regi-
mens, including different values of infusion time, MIC
values, sum of QF and QD, dosage and administration.
As QF +QD increased, % of T >MIC slightly decreased.
In addition, % of T >MIC for 1 h infusion was higher
than that for 0.5 h infusion under the same conditions
of QF + QD and administration dose. The most effective
regimen was 300 mg every 6 h given by 1 h infusion,
with a QF +QD value of 1.5 L/h. This method could
achieve % of T >MIC of 82.8 % at MIC = 4 μg/mL, and
35.1 % at MIC = 8 μg/mL.
Based on Monte Carlo simulation of the case of 0.5 h
infusion, the PK/PD breakpoint was 0.5 μg/mL in the
regimen of dosage 300 mg every 12 h, and was 1.0 μg/
mL in the regimens of dosage 300 mg every 8 h, dosage
300 mg every 6 h, and dosage 600 mg every 12 h (Fig. 5).
In the case of 1 h infusion, the PK/PD breakpoint was
1.0 μg/mL in the regimen of dosage 300 mg every 12 h,
and 2.0 μg/mL in the regimens of dosage 300 mg every
8 h, dosage 300 mg every 6 h, and dosage 600 mg every
12 h. The PTAs were greater for 1 h infusion than for
0.5 h infusion in all cases. Among them, PTA of the
regimen of dosage 300 mg every 6 h showed the highest
value (90.2 %). The Japan Society of Chemotherapy de-
fines the clinical breakpoint as more than 80 %, though
more than 90 % of the PTA has become a reference
value of the PK/PD breakpoint outside of Japan.
Discussion
In this study, we investigated the PK of BIPM using
compartmental and non-compartmental analysis in pa-
tients undergoing CHDF who had various levels of renal
function, and examined the suitability of various admin-
istration regimens in terms of PK/PD breakpoint for
various bacteria, by means of Monte Carlo simulation.
Ikawa et al. analyzed time courses of BIPM concentra-
tion in plasma and FD after single administration in
renal failure patients undergoing CHDF [18]. Here, we
aimed to obtain a model to analyze the results of re-
peated administration of BIPM in patients undergoing
CHDF who retained various levels of renal function.
Time courses of BIPM concentration in plasma and FD
in patients undergoing CHDF closely fitted the observed
values, suggesting that the constructed model formula

















A 37.7 37.6 1.00 7.96 0.33 11.92 11.29 3.99 3.20
B 72.4a 79.7a 1.10 4.14 0.46 15.93 12.09 3.97 5.43
C 63.2 61.2 0.97 4.75 0.30 20.08 19.43 3.42 3.62
D 31.4 29.9 0.95 9.54 0.35 12.15 9.13 2.05 2.20
E 54.3 55.3 1.02 5.53 0.33 19.42 19.55 2.83 2.73
F 32.2 29.9 0.93 9.32 0.24 23.93 15.37 1.38 1.25
G 78.2 79.6 1.02 3.84 0.17 25.80 24.24 3.39 3.66
Mean 1.00 6.44 0.31 3.00 3.15
SD 0.06 2.45 0.09 0.99 1.31
AUC0→τ, plasma area under the plasma concentration-time curve from time 0 to next infusion; AUC0→τ, FD area under the filtrate-dialysate concentration-time curve
from time 0 to next infusion; SC sieving coefficient (AUC0→τ, FD/AUC0→τ, Plasma); CLtot total clearance (300/AUC0→τ, plasma); Vdss volume of distribution at the steady
state; Cmax,plasma maximum concentration of BIPM in plasma; Cmax, FD maximum concentration of BIPM in filtrate-dialysate; T1/2, plasma elimination half-life of BIPM in
plasma; T1/2, FD elimination half-life of BIPM in filtrate-dialysate; SD standard deviation
aAUC0→∞
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successfully represents the results of repeated adminis-
tration of BIPM in patients undergoing CHDF. In the
present study, SC (indicating penetration from blood to
dialyzer) was almost 1.0 for the PS membrane material,
which is almost the same as the value for PMMA mem-
brane [18, 24]. Thus, there appears to be essentially no
difference between PS and PMMA membranes in regard
to drug penetration [18]. These results seem consistent
with the characteristics of BIPM, such as low molecular
weight and low protein binding rate.
We found a strong correlation between the sum of
CLnon-CHDF and CLCHDF obtained by compartmental ana-
lysis and total clearance obtained by non-compartmental
analysis (r2 = 1.00), indicating that the compartment
model formula was appropriate. Ikawa et al. reported that
CLCHDF (1.29 ± 0.08 L/h) was almost the same as the
sum of QF and QD (1.4 L/h) in CHDF with a PMMA
membrane [18]. Suyama et al. also reported that CLCHDF
(1.28 ± 0.14 L/h) was almost the same as the sum of QF
and QD (1.4 L/h) in CHDF with a PMMA membrane [24].
In this study, CLCHDF (1.5 ± 0.1 L/h) estimated by com-
partmental analysis was similar to the sum of QF and QD
(1.5–1.7 L/h) in CHDF with a PS membrane. Considering
the SC estimated by non-compartmental analysis, CLCHDF
of BIPM would be determined by the sum of dialysate flow
rate and filtration flow rate. On the other hand, CLnon-CHDF
represents the sum of non-renal clearance and residual
renal clearance. Metabolism of BIPM in kidney and other
tissues would contribute to CLnon-CHDF. Nakajima et al.
detected two DHP-1 metabolites of BIPM, L-cysteine and
L-cystine, in urine, and reported that excretion of urinary
metabolites accounted for approximately 15 % of total
clearance; these metabolites were not detected in plasma,
suggesting that metabolism of BIPM in kidney contributes
to residual renal clearance [19]. DHP-1 is also expressed in
the ascending colon and ileum as well as the kidney, and
Fig. 2 Typical fittings between the plasma and FD concentration simulation curves and the observed values. Simulation curves of plasma
(open circles, solid line) and FD (closed triangle, dotted line) concentration were obtained by compartmental analysis
Table 3 Pharmacokinetic parameters of biapenem after intravenous administration of biapenem (300 mg) during CHDF




−1) CLCHDF (L/hr) CLnon-CHDF (L/hr)
A 11.09 2.26 1.10 0.56 0.14 1.53 6.24
B 17.45 0.33 0.66 0.15 0.09 1.65 2.54
C 9.51 0.74 0.92 0.33 0.16 1.55 3.11
D 23.84 0.18 1.13 0.34 0.06 1.43 8.04
E 11.74 0.26 0.51 0.33 0.14 1.63 3.93
F 10.19 0.69 1.08 0.78 0.14 1.39 7.92
G 10.43 0.79 1.25 0.22 0.15 1.53 2.27
Mean 13.46 0.75 0.95 0.39 0.13 1.53 4.86
SD 5.29 0.71 0.27 0.22 0.04 0.10 2.50
V1 Volume of distribution of central compartment; k12 transfer rate constant from central compartment to peripheral compartment; k21 transfer rate constant from
peripheral compartment to central compartment; k10 elimination rate constant from central compartment; k13 transfer rate constant from central compartment to
filtrate-dialysate side compartment (QF + QD) · SC/V1; CLCHDF clearance by CHDF (QF + QD) · SC; CLnon-CHDF clearance by non-CHDF routes (k10 · V1); SD standard deviation
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the activity of DHP-1 in ileum has been reported to be
twice that in kidney, suggesting that non-renal DHP-1
function in ileum would also contribute to non-renal clear-
ance [25]. The relationship between GFR calculated before
CHDF application and CLnon-CHDF was given by y = 1.86
x + 1.02 (r2 = 0.97) (Fig. 3), and the y-intercept (1.02 L/h)
represents non-renal clearance. Non-renal clearance in
healthy adults can be estimated as approximately 3.23 L/h,
using reported values of total clearance of BIPM in healthy
adults of 12.9 ± 1.2 L/h, and urinary excretion rates of
unchanged and changed BIPM of approximately 60 and
15 %, respectively [19]. Nagashima et al. reported that
non-renal clearance was 2.60 ± 1.55 L/h in patients with
renal failure during dialysis with a PS membrane, while
CLtot in patients was 2.62 ± 0.60 L/h without HD, so that
CLtot was the same as non-renal clearance in patients with
renal failure [17]. Non-renal clearance in the present study
was a half to one-third of those values. After extracting
patients with sepsis from Fig. 3, the y-intercept took a
negative value (data not shown), indicating that non-renal
clearance would be almost zero in patients with sepsis. In
sepsis, hepatic clearance and renal clearance would be
diminished owing to the reduced function of systemic
organs and impaired blood flow [26], leading to loss of
DHP-1 activity in the kidney and other organs. Thus, we
consider that the reason why average non-renal clearance
in this study was lower than in previous studies is the low
values in patients with sepsis.
We investigated the variation in % of T >MIC based
on the average values of the PK parameters obtained by
compartmental analysis for different regimens, including
dose, dosing interval, infusion time, and CHDF condi-
tions applied in our hospital. The % of T >MIC4 μg/mL
was more than 40 % in all regimens of 900 mg or more
daily dose, regardless of the CHDF conditions and in-
fusion time. Ikawa et al. also reported that although
the regimen of 300 mg every 12 h failed to achieve
T >MIC4 μg/mL of more than 40 %, the regimen of
600 mg every 12 h did do so [18]. These results indi-
cate that the minimum dosage regimen required to
achieve T >MIC4 μg/mL of more than 40 % is 300 mg every
8 h (total amount: 900 mg). On the other hand, no regi-
men gave % of T >MIC8 μg/mL of more than 40 %, sug-
gesting that these regimens could not achieve the
maximal kill end point. However, since the % of T >MIC
values obtained using average PK parameters do not
reflect variations of CLnon-CHDF associated with partial
Fig. 4 Values of T > MIC of 4 μg/mL and 8 μg/mL in different regimens. Panel a represents the case of MIC = 4 μg/mL and infusion time 1 h;
Panel b represents the case of MIC = 4 μg/mL and infusion time 0.5 h; Panel c represents the case of MIC = 8 μg/mL and infusion time 1 h; Panel d
represents the case of MIC = 8 μg/mL and infusion time 0.5 h. The solid line represents 40 % T >MIC. The dotted line represents 20 % T >MIC
Fig. 3 Correlation between individual GFR and CLnon-CHDF. The solid
line indicates the linear regression line
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kidney function, these values may not be adequate as a
clinical indicator.
Monte Carlo simulation is a computer modeling process
that incorporates variability in pharmacokinetic parame-
ters and the natural MIC distribution within a bacterial
population. It can be used to develop interpretive suscep-
tibility criteria based on PK/PD breakpoints [27]. In this
study, Monte Carlo simulations with 10,000 cases were
performed to examine PK/PD breakpoint using the mean
and variance of the PK parameters. As regards infusion
time, the PK/PD breakpoint obtained for all regimens with
1 h infusion was higher than that for 0.5 h infusion, sug-
gesting that the 1 h infusion provides a better outcome. In
this study, the highest PK/PD breakpoint (over 80 % PTA)
was 2 μg/mL with 300 mg every 8 h, 300 mg every 6 h,
and 600 mg every 12 h, indicating that these regimens
provide a sufficient bactericidal effect in the case of bac-
teria with MIC2 μg/mL, but not MIC4 μg/mL. In order to ob-
tain an antimicrobial effect of BIPM towards high MIC
bacteria (more than 4 μg/mL), such as Pseudomonas aeru-
ginosa, higher dose administration and an appropriate
regimen would be needed, although the maximum permit-
ted dose of BIPM in Japan has been set at 1,200 mg/day.
Among the regimens examined in this study, 300 mg
every 6 h with infusion for 1 h was the optimal regimen,
and PTA at MIC2 μg/mL was 90.2 %. Although maximum
MIC more than 80 % is adopted as the PK/PD breakpoint
in Japan, most other countries define it as more than 90 %
[27], so the regimen of 300 mg every 6 h with infusion for
1 h also meets the international standard for MIC2 μg/mL
bacteria. Although the PK/PD breakpoint is expected to
become a decision criterion for individualized and opti-
mized antibacterial therapy, it is focused primarily on the
antibacterial agent. In the future, it will be important to
take bacterial character into account as well, for example,
by means of antimicrobial susceptibility testing and identi-
fication of the causative bacteria of infectious diseases.
The present study has several limitations. Firstly, we
performed the Monte Carlo simulation using the mean
and variance of the PK parameters obtained with the
standard two-stage method because of the small number
of cases (total, 7 cases), and this might have resulted in
overestimation of the inter-individual variation com-
pared to population pharmacokinetics analysis, such as
nonlinear mixed effects modelling (NONMEM®). Fur-
ther, we did not include a parameter of renal function
(e.g. GFR or creatinine clearance) in the Monte Carlo
simulation, even though BIPM clearance is correlated
with renal function. Therefore, as a next step, it would
be desirable to identify the PK/PD breakpoint more pre-
cisely in patients undergoing CHDF by means of Monte
Carlo simulation of BIPM using population pharmacoki-
netic parameters including renal function (e.g. GFR and
creatinine clearance), based on larger numbers of pa-
tients with various levels of renal function. In addition,
from the viewpoint of clinical applicability, we did not
establish that the optimal regimen (300 mg every 6 h
with infusion for 1 h) determined by Monte Carlo simu-
lation is safe, because only one patient received the opti-
mal regimen in this study. Therefore, it is impossible to
evaluate the safety of optimal regimen. However, the
simulated maximum steady-state plasma concentration
Fig. 5 PTA of 40 % T >MIC in plasma at specific MICs for different BIPM regimens. The dotted line represents 80 % PTA. Panel a: infusion time of
1 h; Panel b: infusion time of 0.5 h
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with the optimal regimen in the present study was ap-
proximately 11–24 μg/mL. This concentration is lower
than the maximum steady-state plasma concentration
after administration of 600 mg by 1 h infusion every
12 h in healthy adults (32.4 ± 2.32 μg/mL) [19]. There-
fore, it seems likely that the optimal regimen would be
safe even in renal dysfunction patients undergoing
CHDF. Nevertheless, it will be important to confirm the
safety of the optimal regimen, and clinicians should
carefully consider the appropriate regimen when admin-
istering BIPM to renal dysfunction patients undergoing
CHDF, in addition to monitoring for side effects.
Conclusions
In the present study, we used PK modeling to establish
the optimal regimen of BIPM in patients with various
levels of renal function undergoing CHDF. Clearance of
CHDF was determined by the flow rate of dialysate and
filtration conditions, since almost BIPM flowed into the
dialyzer. The results of Monte Carlo simulation indi-
cated that the regimen of 300 mg every 6 h infusion for
1 h was optimal, compared to other regimens used in
our hospital. This regimen showed effective antibacterial
activity towards MIC2 μg/mL bacteria.
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